Top

Published in:

Open Access 01-12-2015 | Study protocol

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Authors: Danuta M Lisiecka, John Suckling, Thomas RE Barnes, Imran B Chaudhry, Paola Dazzan, Nusrat Husain, Peter B Jones, Eileen M Joyce, Stephen M Lawrie, Rachel Upthegrove, Bill Deakin

Published in: Trials | Issue 1/2015

Abstract

Background

Negative symptoms of psychosis do not respond to the traditional therapy with first- or second-generation antipsychotics and are among main causes of a decrease in quality of life observed in individuals suffering from the disorder. Minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties has been suggested as a new potential therapy for negative symptoms. In the two previous clinical trials comparing minocycline and placebo, both added to the standard care, patients receiving minocycline showed increased reduction in negative symptoms. Three routes to neuroprotection by minocycline have been identified: neuroprotection against grey matter loss, anti-inflammatory action and stabilisation of glutamate receptors. However, it is not yet certain what the extent of the benefit of minocycline in psychosis is and what its mechanism is. We present a protocol for a multi-centre double-blind randomised placebo-controlled clinical trial entitled The Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism (BeneMin).

Methods

After providing informed consent, 226 participants in the early phase of psychosis will be randomised to receive either 100 mg modified-release capsules of minocycline or similar capsules with placebo for 12 months in addition to standard care. The participants will be tested for outcome variables before and after the intervention period. The extent of benefit will be tested via clinical outcome measures, namely the Positive and Negative Syndrome Scale score, social and cognitive functioning scores, antipsychotic medication dose equivalent and level of weight gain. The mechanism of action of minocycline will be tested via blood screening for circulating cytokines and magnetic resonance imaging with three-dimensional T1-weighted rapid gradient-echo, proton density T2-weighted dual echo and T2*-weighted gradient echo planar imaging with N-back task and resting state. Eight research centres in UK and 15 National Health Service Trusts and Health Boards will be involved in recruiting participants, performing the study and analysing the data.

Discussion

The BeneMin trial can inform as to whether in minocycline we have found a new and effective therapy against negative symptoms of psychosis.

The European Union Clinical Trial Register: EudraCT 2010-022463-35 with the registration finalised in July 2011. The recruitment in the trial started in January 2013 with the first patient recruited in March 2013.

Patterson TL, Kaplan RM, Grant I, Semple SJ, Moscona S, Koch WL, et al. Quality of well-being in late-life psychosis. Psychiatry Res. 1996;63:169–81.PubMed

Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:203–9.PubMedPubMedCentral

American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.

Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68.PubMed

Ho B-C, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatr. 1998;155:1196–201.PubMed

Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry. 2000;177:511–5.PubMed

Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975–83.PubMed

McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999;46:899–907.PubMed

Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65:634–40.PubMed

10.

Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatr. 2005;162:1785–804.PubMed

11.

Waddington J, Youssef H, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med. 1995;25:849–57.PubMed

12.

Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:304–7.

13.

Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;37:222–6.

14.

Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185–93.PubMed

15.

Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138.PubMed

16.

Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term‐term neuroprotection. Pharmacotherapy. 2006;26:515–21.PubMedPubMedCentral

17.

Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist. 2005;11:308–22.PubMed

18.

Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 2003;126:1628–37.PubMed

19.

Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003;53:267–70.PubMed

20.

Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355–66.PubMed

21.

Sakata H, Niizuma K, Yoshioka H, Kim GS, Jung JE, Katsu M, et al. Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats. J Neurosci. 2012;32:3462–73.PubMedPubMedCentral

22.

Koistinaho J, Koistinaho M. Minocycline, a tetracycline derivative, as a potential protective agent for acute stroke. In: Immunological mechanisms and therapies in brain injuries and stroke. New York: Springer; 2014. p. 275–85.

23.

Fan X, Lo EH, Wang X. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke. 2013;44:745–52.PubMedPubMedCentral

24.

Dixit A, Srivastava G, Verma D, Mishra M, Singh PK, Prakash O, et al. Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson’s disease. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2013;1832:1227–40.

25.

Inamdar AA, Chaudhuri A, O’Donnell J. The protective effect of minocycline in a paraquat-induced Parkinson’s disease model in Drosophila is modified in altered genetic backgrounds. Park Dis. 2012;2012:1–16.

26.

Kim H-S, Suh Y-H. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196:168–79.PubMed

27.

Whitford TJ, Grieve SM, Farrow TF, Gomes L, Brennan J, Harris AW, et al. Progressive grey matter atrophy over the first 2–3 years of illness in first-episode schizophrenia: a tensor-based morphometry study. Neuroimage. 2006;32:511–9.PubMed

28.

Chua SE, Cheung C, Cheung V, Tsang JT, Chen EY, Wong JC, et al. Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89:12–21.PubMed

29.

Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191:325–34.PubMed

30.

Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281–8.PubMed

31.

Malla AK, Bodnar M, Joober R, Lepage M. Duration of untreated psychosis is associated with orbital–frontal grey matter volume reductions in first episode psychosis. Schizophr Res. 2011;125:13–20.PubMed

32.

Cahn W, Van Haren N, Pol HH, Schnack H, Caspers E, Laponder D, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 2006;189:381–2.PubMed

33.

Bastos LFS, Merlo LA, Rocha LTS, Coelho MM. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. Eur J Pharmacol. 2007;576:171–9.PubMed

34.

Wang J, Wei Q, Wang C-Y, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem. 2004;279:19948–54.PubMed

35.

Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63:257–65.PubMed

36.

van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative < i > (R)</i > −[< sup > 11</sup > C] PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820–2.PubMed

37.

Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia - a case–control study. J Mol Neurosci. 2010;42:112–9.PubMed

38.

van Kammen D, McAllister C, Kelley M. Relationship between immune and behavioral measures in schizophrenia. Vienna: Springer; 1997.

39.

Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155:101–8.PubMed

40.

Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.PubMedPubMedCentral

41.

Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study. JAMA Psychiatry. 2014;71:1121–8.PubMedPubMedCentral

42.

Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33:523–33.PubMed

43.

Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. 1996.

44.

Deakin JW, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco–magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154–64.PubMed

45.

Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–18.PubMed

46.

Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of thrombin‐induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2005;95:1755–65.PubMed

47.

Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos JV, Cordeiro RC, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013;27:1032–43.PubMed

48.

Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatr. 2001;158:1367–77.PubMed

49.

Lee I, Kesner RP. Differential contribution of NMDA receptors in hippocampal subregions to spatial working memory. Nat Neurosci. 2002;5:162–8.PubMed

50.

Lisman JE, Fellous J-M, Wang X-J. A role for NMDA-receptor channels in working memory. Nat Neurosci. 1998;1:273–5.PubMed

51.

Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51:390–431.PubMedPubMedCentral

52.

Fanning WL, Gump DW, Sofferman RA. Side effects of minocycline: a double-blind study. Antimicrob Agents Chemother. 1977;11:712–7.PubMedPubMedCentral

53.

Goulden V, Glass D, Cunliffe W. Safety of long‐term high‐dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693–5.PubMed

54.

Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329–42.PubMed

55.

Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169–72.PubMedPubMedCentral

56.

Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;8, CD002086.PubMed

57.

Good M, Hussey D. Minocycline: stain devil? Br J Dermatol. 2003;149:237–9.PubMed

58.

White SW, Besanceney C. Systemic pigmentation from tetracycline and minocycline therapy. Arch Dermatol. 1983;119:1–2.PubMed

59.

Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69–75.PubMed

60.

Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res. 1991;4:109–20.PubMed

61.

Yang S, Yang YK, Chong M, Yang Y, Chang W, Lai C. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical Pharmacology & Therapeutics. 2007;81:586–94.

62.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.PubMed

63.

Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics. CNS Drugs. 2007;21:911–36.PubMed

64.

Henderson DC. Atypical antipsychotic-induced diabetes mellitus. CNS Drugs. 2002;16:77–89.PubMed

65.

Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2007;69:18–31.

66.

Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6:3.PubMedPubMedCentral

67.

Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24:S7–14.PubMed

68.

Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker W, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61:1356–70.PubMed

69.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatr. 2003;160:1396–404.PubMed

70.

Ferguson-Smith AC, Chen Y-F, Newman MS, May LT, Sehgal PB, Ruddle FH. Regional localization of the interferon-β2B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics. 1988;2:203–8.PubMed

71.

Suckling J, Barnes A, Job D, Brennan D, Lymer K, Dazzan P, et al. The neuro/PsyGRID calibration experiment. Hum Brain Mapp. 2012;33:373–86.PubMed

72.

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79:231–8.PubMed

73.

Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261.PubMed

74.

Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25:329–43.PubMed

75.

Hall RC. Global assessment of functioning: a modified scale. Psychosomatics. 1995;36:267–75.PubMed

76.

Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol. 2002;41:417–22.PubMed

77.

Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853–9.PubMed

78.

Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of the WAIS-III for use with patients with schizophrenia. Schizophr Res. 2000;46:209–15.PubMed

79.

Leeson VC, Barnes TR, Harrison M, Matheson E, Harrison I, Mutsatsa SH, et al. The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr Bull. 2010;36:400–9.PubMed

80.

Green RE, Melo B, Christensen B, Ngo L-A, Monette G, Bradbury C. Measuring premorbid IQ in traumatic brain injury: an examination of the validity of the Wechsler Test of Adult Reading (WTAR). J Clin Exp Neuropsychol. 2008;30:163–72.PubMed

81.

Wechsler D. Wechsler test of adult reading: WTAR. New York: Psychological Corporation; 2001.

82.

Joyce E, Collinson S, Crichton P. Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia. Psychol Med. 1996;26:39–49.PubMed

83.

Lezak MD. Neuropsychological assessment. New York: Oxford University Press; 2004.

84.

Rey A. L’examen clinique en psychologie. 1958.

85.

Schmidt M. Rey auditory verbal learning test: a handbook. Los Angeles: Western Psychological Services; 1996.

86.

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–7.PubMed

87.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209–14.PubMed

88.

Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314–25.PubMed

89.

Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci. 1994;91:3652–6.PubMedPubMedCentral

90.

Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–42.PubMed

91.

Emsley H, Smith C, Georgiou R, Vail A, Hopkins S, Rothwell N, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:1366–72.PubMedPubMedCentral

92.

Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol. 2007;7:5.PubMedPubMedCentral

93.

Holt I, Cooper R, Denton J, Meager A, Hopkins S. Cytokine inter-relationships and their association with disease activity in arthritis. Rheumatology. 1992;31:725–33.

94.

Zhang J, Tong L, Wang L, Li N. Texture analysis of multiple sclerosis: a comparative study. Magn Reson Imaging. 2008;26:1160–6.PubMed

95.

Klingberg T, O’Sullivan BT, Roland PE. Bilateral activation of fronto-parietal networks by incrementing demand in a working memory task. Cereb Cortex. 1997;7:465–71.PubMed

96.

Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: evidence from a partial correlation network analysis. Neuroimage. 2008;42:1178–84.PubMed

97.

Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci. 2003;100:253–8.PubMed

98.

Barnes A, Bullmore ET, Suckling J. Endogenous human brain dynamics recover slowly following cognitive effort. PLoS One. 2009;4:e6626.PubMedPubMedCentral

99.

Owen AM, McMillan KM, Laird AR, Bullmore E. N‐back working memory paradigm: a meta‐analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005;25:46–59.PubMed

100.

Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–91.PubMedPubMedCentral

101.

Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11:239–44.PubMed

102.

Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;45:11–9.

103.

Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–6.PubMed

104.

Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173:353–7.PubMed

105.

Yusufi B, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes T. Reliability of the antipsychotic non-neurological side effects rating scale (ANNSERS). J Psychopharmacol. 2005;19:A10.

106.

Hayward P. Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health. 1995;4:511–8.

107.

Everitt B, Pickles A. Statistical aspects of the design and analysis of clinical trials. London: World Scientific; 2004.

108.

Heyting A, Tolboom J, Essers J. Statistical handling of drop‐outs in longitudinal clinical trials. Stat Med. 1992;11:2043–61.PubMed

109.

Dunn G, Maracy M, Dowrick C, Ayuso-Mateos J, Dalgard O, Page H, et al. The Outcomes of Depression International (ODIN) Group (2003). Estimating psychological treatment effects from an RCT with both non-compliance and loss to follow-up. Br J Psychiatry. 2003;183:323–31.PubMed

110.

Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14:369–95.PubMed

111.

Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res. 2010;19:237–70.PubMed

112.

Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143–56.PubMed

113.

Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007;130:2375–86.PubMed

114.

De Stefano N, Matthews P, Filippi M, Agosta F, De Luca M, Bartolozzi M, et al. Evidence of early cortical atrophy in MS Relevance to white matter changes and disability. Neurology. 2003;60:1157–62.PubMed

115.

Zarahn E, Aguirre GK, D’Esposito M. Empirical analyses of BOLD fMRI statistics. Neuroimage. 1997;5:179–97.PubMed

116.

Suckling J, Ohlssen D, Andrew C, Johnson G, Williams SC, Graves M, et al. Components of variance in a multicentre functional MRI study and implications for calculation of statistical power. Hum Brain Mapp. 2008;29:1111–22.PubMed

117.

Mori S, Wakana S, Van Zijl PC, Nagae-Poetscher L. MRI atlas of human white matter. 2005.

118.

Rissman J, Gazzaley A, D’Esposito M. Measuring functional connectivity during distinct stages of a cognitive task. Neuroimage. 2004;23:752–63.PubMed

119.

Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014;92:381–97.PubMedPubMedCentral

Title: The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial
Authors: Danuta M Lisiecka
John Suckling
Thomas RE Barnes
Imran B Chaudhry
Paola Dazzan
Nusrat Husain
Peter B Jones
Eileen M Joyce
Stephen M Lawrie
Rachel Upthegrove
Bill Deakin
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-015-0580-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial

Abstract

Background

Methods

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Please log in to get access to this content

Other articles of this Issue 1/2015

Face-to-face individual counseling and online group motivational interviewing in improving oral health: study protocol for a randomized controlled trial

Oropharyngeal administration of mother’s colostrum, health outcomes of premature infants: study protocol for a randomized controlled trial

A living document: reincarnating the research article

Combining behavioural activation with physical activity promotion for adults with depression: findings of a parallel-group pilot randomised controlled trial (BAcPAc)

Outcome reporting in randomised controlled trials and meta-analyses of appendicitis treatments in children: a systematic review

Effects of study design and allocation on self-reported alcohol consumption: randomized trial